Healthcare Services

A key trend shaping the Endocrine Peptide Test Market involves the Advancements in Immunoassay Testing Systems for Endocrine Peptide Testing

April 1, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Endocrine Peptide Test Market At The End Of The 2026–2030 Forecast Period?

The endocrine peptide test market size has seen robust growth in recent years. It is projected to increase from $9.95 billion in 2025 to $10.88 billion in 2026, representing a compound annual growth rate (CAGR) of 9.3%. Historically, this expansion has been attributed to the rise in endocrine disorders, the proliferation of diagnostic laboratories, increased awareness of hormone imbalances, progress in immunoassay techniques, and the broader development of clinical endocrinology.

The endocrine peptide test market is projected to experience substantial expansion over the coming years, reaching $14.88 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.1%. This anticipated growth during the forecast period is primarily due to factors such as the increasing adoption of precision medicine, advancements in biomarker research, enhanced automation in diagnostic laboratories, the rise of personalized endocrine care, and a growing demand for early diagnosis. Key trends expected to shape the market during this period encompass a heightened need for diagnostics for hormone disorders, the greater utilization of peptide biomarkers, advancements in detecting endocrine diseases earlier, the broadening of specialized laboratory testing, and an emphasis on precise hormonal monitoring.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16675&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Endocrine Peptide Test Market?

The increasing occurrence of diabetes is projected to fuel the growth of the endocrine peptide test market in the future. Diabetes refers to a collection of diseases that lead to elevated blood sugar (glucose) levels. The widespread nature of diabetes is expanding due to factors such as unhealthy diets, inactive lifestyles, genetic predispositions, and an aging populace. Endocrine peptide tests, which encompass hemoglobin A1c, fasting plasma glucose, and C-peptide tests, are utilized in diabetes for diagnosing the condition, monitoring glucose levels, and assessing insulin production and sensitivity. For instance, in June 2024, according to the National Health Service (NHS), a UK-based government department, the number of individuals under 40 diagnosed with diabetes saw a significant rise, increasing from 173,166 in 2022 to 216,440 in 2023. This sharp increase underscores a concerning trend of growing diabetes prevalence among younger populations. Therefore, the expanding prevalence of diabetes is propelling the endocrine peptide test market.

What Segment Types Make Up The Endocrine Peptide Test Market?

The endocrine peptide test market covered in this report is segmented –

1) By Test-Type: Dehydroepiandrosterone Sulphate, Progesterone, Luteinizing Hormone, Thyroid Prolactin, Oestradiol, Human Chorionic Gonadotropin, Thyroid-Stimulating Hormone, Other Test-Types

2) By Technology: Mass Spectroscopy, Immunoassay, Chromatography, Nucleic Acid Based, Other Technologies

3) By End-User: Clinics, Healthcare Centers, Hospitals, Commercial Laboratories

Subsegments:

1) By Dehydroepiandrosterone Sulphate (DHEA-S): Immunoassay Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)

2) By Progesterone: Immunoassay Tests, Chemiluminescence Assays, ELISA Tests

3) By Luteinizing Hormone: Immunoassay Tests, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA)

4) By Thyroid Prolactin: Immunoassay Tests, Chemiluminescence Assays, Radioimmunoassay (RIA)

5) By Oestradiol: Immunoassay Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)

6) By Human Chorionic Gonadotropin (hCG): Immunoassay Tests, Chemiluminescence Assays, Enzyme Immunoassay (EIA)

7) By Thyroid-Stimulating Hormone (TSH): Immunoassay Tests, Radioimmunoassay (RIA), Enzyme-Linked Immunosorbent Assay (ELISA)

8) By Other Test-Types: Cortisol, Insulin, Growth Hormone (GH), Parathyroid Hormone (PTH)

What Trends Are Projected To Affect The Endocrine Peptide Test Market?

Major companies operating in the endocrine peptide test market are developing immunoassay testing systems to enhance the accuracy, sensitivity, and speed of endocrine peptide testing. These systems utilize antibodies to detect and measure specific peptides present in blood or urine samples, thereby supplying healthcare professionals with valuable information regarding hormone levels and endocrine function. For instance, in July 2023, Siemens Healthineers, a German-based healthcare services company, introduced the Atellica CI Analyzer, a compact system for immunoassay and clinical chemistry testing, including assays for endocrine peptides. The analyzer also features a reproductive endocrinology menu that incorporates anti-Mullerian hormone (AMH) for determining ovarian reserve, as well as sFlt-1 and PlGF (placental growth factor) to aid in the prognosis of preeclampsia. The Atellica CI Analyzer is designed to deliver quality results quickly and consistently, with a capacity of up to 1000 tests per hour, providing workflow efficiency and flexibility to help labs meet evolving testing needs.

Who Are The Key Players Driving Competition In The Endocrine Peptide Test Market?

Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories

Read the full endocrine peptide test market report here:

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Which Regions Are Projected To Dominate The Endocrine Peptide Test Market In The Coming Years?

North America was the largest region in the endocrine peptide test market in 2025. The regions covered in the endocrine peptide test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Endocrine Peptide Test Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16675&type=smp

Browse Through More Reports Similar to the Global Endocrine Peptide Test Market 2026, By The Business Research Company

Hepatic Encephalopathy Global Market Report

https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report

Esophageal Dysphagia Global Market Report

https://www.thebusinessresearchcompany.com/report/esophageal-dysphagia-global-market-report

Encephalitis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/encephalitis-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795